Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
The clinical behavior of prostate cancer (PCa) is variable, and while the majority of cases remain indolent, 10% of patients progress to deadly forms of the disease. Current clinical predictors used at the time of diagnosis have limitations to accurately establish progression risk. | A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer